StockData
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. (LENZ) stock

LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3055% below fair value
$3.50−0.32 (-8.38%)

Close on Nov 17, 2026Market cap $109.97MP/E –Yield –

LENZ Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

LENZ Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $3.79M, down 86.1% year over year. For fiscal 2025 it was $18.67M, down 37.4% from the year before. The highest annual figure on record is $72.79M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$18.67M-37.4%
FY2024Dec 31, 2024$29.80M-49.9%
FY2023Dec 31, 2023$59.50M-18.2%
FY2022Dec 31, 2022$72.79M+91.9%
FY2021Dec 31, 2021$37.93M+315.8%
FY2020Dec 31, 2020$9.12M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0-100.0%
Q1 FY2026Mar 31, 2026$0-100.0%
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$3.79M-41.2%
Q2 FY2025Jun 30, 2025$9.06M+30.5%
Q1 FY2025Mar 31, 2025$5.82M-44.8%
Q4 FY2024Dec 31, 2024$5.87M-70.0%
Q3 FY2024Sep 30, 2024$6.45M-62.1%
Q2 FY2024Jun 30, 2024$6.95M-45.1%
Q1 FY2024Mar 31, 2024$10.54M+2.1%
Q4 FY2023Dec 31, 2023$19.54M+5.8%
Q3 FY2023Sep 30, 2023$17.00M-7.1%
Q2 FY2023Jun 30, 2023$12.64M-28.9%
Q1 FY2023Mar 31, 2023$10.33M-43.4%
Q4 FY2022Dec 31, 2022$18.46M+64.8%
Q3 FY2022Sep 30, 2022$18.30M+110.8%
Q2 FY2022Jun 30, 2022$17.78M+40.3%
Q1 FY2022Mar 31, 2022$18.25M+239.3%
Q4 FY2021Dec 31, 2021$11.21M+75.4%
Q3 FY2021Sep 30, 2021$8.68M+275.9%
Q2 FY2021Jun 30, 2021$12.67M+2894.6%
Q1 FY2021Mar 31, 2021$5.38M–
Q4 FY2020Dec 31, 2020$6.39M–
Q3 FY2020Sep 30, 2020$2.31M–
Q2 FY2020Jun 30, 2020$423.00K–

More LENZ Therapeutics figures

See a number that looks wrong?